Nicotinamide Supplementation in Glaucoma

The goal of this clinical trial is to learn if nicotinamide (NAM, vitamin B3) supplementation can delay glaucoma progression 30% above that achieved with conventional glaucoma treatment using topical medication. The main questions it aims to answer are: Can NAM supplementation improve the visual function of patients with glaucoma measured by visual field perimetry? Researchers will compare NAM to a placebo (a look-alike substance that contains no drug) to see if NAM works as an adjuvant in glaucoma treatment. Participants will: * Take NAM or a placebo every day for 2 years * Visit the clinic once every 3-4 months for checkups and tests

NCT Number	NCT06731582
Lead Sponsor	Singapore Eye Research Institute Collaborators: National University Hospital, Singapore, Singapore National Eye Centre
Conditions	Glaucoma
Enrollment	520 participants
Start Date	2024-03-12
Primary Completion	2027-07 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2024-12-12